[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 13, 1975

Drug Development, Regulation, and the Practice of Medicine

Author Affiliations

University of Rochester Medical Center Rochester, NY

JAMA. 1975;231(2):137. doi:10.1001/jama.1975.03240140011010

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

To the Editor.—  I agree with Dr. Nadasdi's observation on the heterogeneity of the medical profession; he is correct in interpreting my point to be that it is the practicing physician who has lost any influence he once had on the process of drug development and regulation.But Dr. Nadasdi himself over-simplifies things by assuming that key decisions in government and the pharmaceutical industry are controlled by medically qualified people. Health policy issues in government are firmly in the hands of such groups as the staffs of Congressional Committees, the Department of HEW, and the Office of Management and Budget. The real decision-makers in these groups are lawyers, administrators and economists. In the pharmaceutical industry, decisions are controlled by the marketing division, the financial department and the scientific research and development division. The decision-makers are business executives, market research experts, accountants and scientists.My point is that the input of

×